

Vera Cappelletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7041413/publications.pdf>

Version: 2024-02-01

86
papers

2,389
citations

236612

25
h-index

233125

45
g-index

87
all docs

87
docs citations

87
times ranked

3678
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma. <i>Clinical Chemistry</i> , 2022, 68, 691-701.	1.5	11
2	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 78.	3.5	15
3	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	1.5	2
4	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	1.3	8
5	A combination of extracellular matrix and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. <i>Molecular Oncology</i> , 2021, 15, 1345-1357.	2.1	6
6	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1409.	1.7	9
7	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2021, 6, 100086.	2.0	31
8	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	1.7	26
9	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
10	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	4.3	26
11	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 146, 3495-3503.	2.3	17
12	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1475.	1.8	25
13	Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 81-91.	0.8	3
14	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	1.7	33
15	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. <i>Cells</i> , 2019, 8, 683.	1.8	21
16	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	1.7	18
17	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	2.6	38
18	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0

#	ARTICLE	IF	CITATIONS
19	A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15637-e15637.	0.8	1
20	Extracellular matrix proteins as diagnostic markers of breast carcinoma. Journal of Cellular Physiology, 2018, 233, 6280-6290.	2.0	49
21	Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells. Annals of Oncology, 2018, 29, 1599-1601.	0.6	12
22	TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Tumori, 2018, 104, 401-405.	0.6	10
23	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 196.	1.8	0
24	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. Seminars in Cancer Biology, 2017, 44, 106-116.	4.3	47
25	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16
26	Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer. Molecular Oncology, 2017, 11, 1399-1412.	2.1	6
27	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. Breast, 2017, 35, 63-68.	0.9	5
28	Metabolic Footprints and Molecular Subtypes in Breast Cancer. Disease Markers, 2017, 2017, 1-19.	0.6	52
29	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. Disease Markers, 2017, 2017, 1-11.	0.6	13
30	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. Advances in Experimental Medicine and Biology, 2017, 994, 83-103.	0.8	10
31	Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. Bladder Cancer, 2016, 2, 395-403.	0.2	13
32	Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer. Microarrays (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf,50 222 Td	1.4	7
33	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clinical Cancer Research, 2016, 22, 337-345.	3.2	58
34	In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. Oncotarget, 2016, 7, 976-994.	0.8	10
35	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. International Journal of Biological Markers, 2015, 30, 429-433.	0.7	26
36	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. British Journal of Cancer, 2015, 113, 290-298.	2.9	40

#	ARTICLE	IF	CITATIONS
37	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	2.3	33
38	Circulating Biomarkers for Prediction of Treatment Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 60-63.	0.9	31
39	Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. <i>Seminars in Cancer Biology</i> , 2015, 35, 3-10.	4.3	120
40	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 278-289.	1.5	19
41	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0123194.	1.1	11
42	Cell cycle dependent oscillatory expression of estrogen receptor- β links Pol II elongation to neoplastic transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9561-9566.	3.3	13
43	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	2.1	39
44	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. <i>PLoS ONE</i> , 2014, 9, e86511.	1.1	10
45	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. <i>Cell Cycle</i> , 2013, 12, 1679-1687.	1.3	109
46	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1014-1014.	0.8	2
47	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 601-610.	1.1	88
48	Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 55-59.	0.9	3
49	Impact of biospecimens handling on biomarker research in breast cancer. <i>BMC Cancer</i> , 2009, 9, 409.	1.1	81
50	PIK3CA cancer mutations display gender and tissue specificity patterns. <i>Human Mutation</i> , 2008, 29, 284-288.	1.1	120
51	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 439-449.	1.6	16
52	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. , 2008, , 15-32.		0
53	Questioning the Utility of Pooling Samples in Microarray Experiments with Cell Lines. <i>International Journal of Biological Markers</i> , 2006, 21, 67-73.	0.7	6
54	Modulation of estrogen receptor- β isoforms by phytoestrogens in breast cancer cells. <i>International Journal of Oncology</i> , 2006, 28, 1185.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. International Journal of Oncology, 2006, 28, 1185-91.	1.4	12
56	Prospective evaluation of estrogen receptor- β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer, 2004, 11, 761-770.	1.6	25
57	Selective modulation of ER- β by estradiol and xenoestrogens in human breast cancer cell lines. Cellular and Molecular Life Sciences, 2003, 60, 567-576.	2.4	25
58	Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status. Journal of the National Cancer Institute, 2003, 95, 629-630.	3.0	11
59	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753.	0.8	20
60	Genistein blocks breast cancer cells in the G2M phase of the cell cycle. Journal of Cellular Biochemistry, 2000, 79, 594-600.	1.2	115
61	Genistein blocks breast cancer cells in the G2M phase of the cell cycle. , 2000, 79, 594.		2
62	The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. British Journal of Cancer, 1999, 80, 1150-1155.	2.9	150
63	Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Letters, 1998, 130, 143-152.	3.2	103
64	int-2 Oncogene amplification and prognosis in node-negative breast carcinoma. , 1997, 74, 620-624.		16
65	Modulation of Cathepsin-D and pS2 Protein Levels in Human Breast Cancer Cell Lines. Tumor Biology, 1996, 17, 290-298.	0.8	9
66	Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Research, 1995, 15, 2551-5.	0.5	25
67	Paracrine interaction in co-culture of hormone-dependent and independent breast cancer cells. Breast Cancer Research and Treatment, 1993, 26, 275-281.	1.1	8
68	Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Research and Treatment, 1993, 26, 7-13.	1.1	13
69	p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1993, 85, 965-970.	3.0	226
70	Clusterin: A potential target for improving response to antiestrogens. International Journal of Oncology, 1992, 33, 791.	1.4	4
71	Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. European Journal of Cancer, 1992, 28, 1315-1318.	1.3	30
72	Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. European Journal of Cancer & Clinical Oncology, 1991, 27, 970-972.	0.9	45

#	ARTICLE	IF	CITATIONS
73	Interaction between hormone-dependent and hormone-independent human breast cancer cells. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1154-1157.	0.9	3
74	Activity of Tamoxifen and Its Metabolites on Endocrine-Dependent and Endocrine-Independent Breast Cancer Cells. <i>Tumor Biology</i> , 1991, 12, 149-158.	0.8	6
75	Influence of culture conditions on the estrogenic cell growth stimulation of human breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1990, 37, 195-200.	1.2	29
76	Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. <i>Anticancer Research</i> , 1990, 10, 1699-705.	0.5	11
77	Progesterone receptor determination in human breast tumors by immunocytochemical and biochemical techniques. <i>Breast Cancer Research and Treatment</i> , 1989, 14, 217-225.	1.1	7
78	Simultaneous Estimation of Epidermal Growth Factor Receptors and Steroid Receptors in a Series of 136 Resectable Primary Breast Tumors. <i>Tumor Biology</i> , 1988, 9, 200-211.	0.8	29
79	Relationship between ER-ICA and conventional steroid receptor assays in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1986, 8, 35-43.	1.1	17
80	Comparison of immunochemical and radioligand binding assays for estrogen receptors in human breast tumors. <i>Cancer Research</i> , 1986, 46, 4278s-4281s.	0.4	11
81	Advances in Renal Cancer: Arguments Against Hormone Therapy. , 1985, , 311-314.		0
82	Prognostic Significance of Progesterone Receptors Alone or in Association with Estrogen Receptors in Human Breast Cancer. <i>Tumori</i> , 1984, 70, 159-164.	0.6	14
83	Distribution of Estrogen and Progesterone Receptors in Primary Tumor and Lymph Nodes in Individual Patients with Breast Cancer. <i>Tumori</i> , 1984, 70, 165-168.	0.6	12
84	Prognostic significance of progesterone receptors alone or in association with estrogen receptors in human breast cancer. <i>Tumori</i> , 1984, 70, 159-64.	0.6	8
85	Distribution of estrogen and progesterone receptors in primary tumor and lymph nodes in individual patients with breast cancer. <i>Tumori</i> , 1984, 70, 165-8.	0.6	3
86	Adjunctive Medroxyprogesterone Acetate to Radical Nephrectomy in Category M(0) Renal Cell Carcinoma. <i>European Urology</i> , 1983, 9, 202-206.	0.9	13